ASCO26: Sara Tolaney, MD, MPH, ASCENT-03 - Summary - MDSpire

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

  • July 1, 2026

Share

Objective:

To present data from the ASCENT-03 study regarding sacituzumab govitecan in advanced triple-negative breast cancer.

Key Findings:
  • The data supports the case for approval of sacituzumab govitecan as a first-line treatment.
Interpretation:

Conclusion:

Original Source(s)

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

  • July 1, 2026

Related Content

Usefulness of indigo carmine chromoendoscopy for detecting gastric cancer and gastric adenoma during upper gastrointestinal endoscopy (INDIGO study): protocol for a prospective multicentre observational study

Development and application of a prognostic model based on radiomics and artificial intelligence for patients with lung adenocarcinoma brain metastasis

Preoperative total cholesterol and axillary lymph node burden in breast cancer: an exploratory analysis with a preliminary nomogram